ClinicalTrials.gg
CompletedNCT07945184Updated Nov 18, 2026

Preoperative Oral Diltiazim Versus Oral Propranolol for Preforming Induced Hypotension in Functional Endoscopic Sinus Surgery

An interventional study of Propranolol and Diltiazem in Oral Diltiazim, Oral Propranolol and Hypotension, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Mar 2024, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Hypotension by Assiut University — 6 open to participants now, 6 under way, 1 of them phase 3. Hypotension · Assiut University.

Enrollment
10th of 16
80 · median 95
Started
2024
with 1 other
No phase
7 of 16
4 open now
Registered
16th of 16
by date

Among the 16 studies in Hypotension by Assiut University, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 7 with no phase, and was the 16th registered.

Hypotension

889 studies on the registry are indexed under Hypotension; 197 are open to participants now.

Browse Hypotension studies →

Open to participants now

6 of the 16 studies in Hypotension by Assiut University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 112 Hypotension studies recruiting now, 51 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hypotension by Assiut University, or all of them as a file.
02

Study summary

This study aims to compare the efficacy of preoperative oral diltiazem and oral propranolol in achieving controlled hypotension during functional endoscopic sinus surgery (FESS).

Read the detailed description

Functional endoscopic sinus surgery (FESS) is the standard minimally invasive surgical approach for the management of chronic rhinosinusitis and other sinonasal diseases refractory to medical treatment.

Propranolol is a non-selective β-adrenergic receptor antagonist that decreases heart rate, myocardial contractility, and cardiac output, thereby reducing arterial blood pressure and attenuating the sympathetic response to laryngoscopy and surgical stimulation.

Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits calcium influx into cardiac myocytes and vascular smooth muscle cells, resulting in arterial vasodilation together with negative chronotropic and mild negative inotropic effects.

03

Conditions studied

  • Oral Diltiazim
  • Oral Propranolol
  • Hypotension
  • Functional Endoscopic Sinus Surgery

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age group between 18 and 60 years.
  • Patients of either gender male or female.
  • (ASA) physical status I and II.
  • Scheduled for functional endoscopic sinus surgery (FESS) procedure under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • Patients with a history of allergy to either propranolol or diltiazim.
  • Patients with uncontrolled hypertension, diabetes mellitus, bronchial asthma, or cardiovascular disease.
  • Patients with hepatic and renal and neurological dysfunction.
  • Patients having coagulation or bleeding disorder.
  • Chronic or acute intake of sedatives or analgesic drugs.
  • Patients on adrenergic blocking drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Group A (Propranolol)

    Patients will receive one tablet (10 mg) of oral propranolol hydrochloride (Inderal) at 8:00 pm the night before surgery, and another one tablet (10 mg) with a small sip of water one hour before induction of anesthesia.

    Drug: Propranolol

  • Experimental
    Group B

    Patients will receive one tablet of oral diltiazem (60 mg) at 8:00 PM on the night before surgery and another (60 mg) tablet with a small sip of water 1 hour before induction of anesthesia.

    Drug: Diltiazem

Interventions

  • Patients will receive one tablet (10 mg) of oral propranolol hydrochloride (Inderal) at 8:00 pm the night before surgery, and another one tablet (10 mg) with a small sip of water one hour before induction of anesthesia.

  • Patients will receive one tablet of oral diltiazem (60 mg) at 8:00 PM on the night before surgery and another (60 mg) tablet with a small sip of water 1 hour before induction of anesthesia.

06

What researchers measure

Primary outcomes

  1. Incidence of hypotension

    Incidence of hypotension will be recorded.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Quality of the surgical field

    The quality of the surgical field will be evaluated using the Fromme-Boezaart Surgical Field Grading Scale, while surgeon satisfaction will be assessed using a 5-point Likert scale (1 = very poor, 2 = poor, 3 = fair, 4 = good, and 5 = excellent)

    Time frame: 24 hours postoperatively

  2. Heart rate

    Heart rate will be recorded at baseline (before administration of the study medication), before induction of anesthesia, after induction, immediately after endotracheal intubation, every 5 minutes throughout surgery, and at the end of the procedure.

    Time frame: Till the end of surgery (Up to 2 hours)

  3. Systolic blood pressure

    Systolic blood pressure will be recorded at baseline (before administration of the study medication), before induction of anesthesia, after induction, immediately after endotracheal intubation, every 5 minutes throughout surgery, and at the end of the procedure.

    Time frame: Till the end of surgery (Up to 2 hours)

  4. Diastolic blood pressure

    Diastolic blood pressure will be recorded at baseline (before administration of the study medication), before induction of anesthesia, after induction, immediately after endotracheal intubation, every 5 minutes throughout surgery, and at the end of the procedure.

    Time frame: Till the end of surgery (Up to 2 hours)

  5. Mean arterial pressure

    Mean arterial pressure will be recorded at baseline (before administration of the study medication), before induction of anesthesia, after induction, immediately after endotracheal intubation, every 5 minutes throughout surgery, and at the end of the procedure.

    Time frame: Till the end of surgery (Up to 2 hours)

  6. Total intraoperative blood loss

    Total intraoperative blood loss will be estimated by measuring the volume of blood collected in the graduated suction canister after subtraction of the irrigation fluid used during surgery.

    Time frame: Intraoperatively

  7. Time to extubation

    Time to extubation (minutes), measured from discontinuation of anesthetic agents until successful tracheal extubation.

    Time frame: Until successful tracheal extubation (Up to 2 hours)

  8. Total intraoperative nitroglycerin consumption

    Total intraoperative nitroglycerin consumption will be recorded.

    Time frame: Intraoperatively

  9. Time to discharge from the post-anesthesia care unit

    Time to discharge from the post-anesthesia care unit (PACU) will be recorded according to standard discharge criteria.

    Time frame: Till the discharge from the post-anesthesia care unit (Up to 2 weeks)

  10. Degree of surgeon satisfaction

    Surgeon satisfaction will be assessed using a 5-point Likert scale (1 = very poor, 2 = poor, 3 = fair, 4 = good, and 5 = excellent).

    Time frame: 24 hours postoperatively

  11. Incidence of adverse events

    Incidence of adverse events such as bradycardia, arrhythmias, bronchospasm, nausea, vomiting, excessive bleeding, or any other drug-related complications.

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Assiut University
    Asyut, 71515, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Feb 2026, 23 months.

Of 212 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's 23 months is above that.

Counting every sponsor, half of 219 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Mar 1, 2024
Primary completionActual
Feb 1, 2026
CompletionActual
Feb 1, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945184
Lead sponsor
Assiut University
Responsible party
Ahmed Mohamed Abdel Motaleb Abdelhafez (Lecturer of Anasthesia and Intensive Care, Assiut University, Egypt, Assiut University) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 1, 2024
Primary completion
Feb 1, 2026
Completion
Feb 1, 2026
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propranolol · Diltiazem

Start the discussion